Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due to Modulation of Proliferative and Invasive Ability of Gastric Cancer

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Wang, Qinchuan ^a,b   Liu, Xiyong ^b   Zhou, Jichun ^a   Huang, Yasheng ^b   Zhang, Shengjie ^a   Shen, Jianguo ^a   Loera, Sofia ^b   Yuan, Xiaoming ^a   Chen, Wenjun ^a   Jin, Mei ^a   Shibata, Stephen ^b   Liu, Yingbin ^c   Chu, Peiguo ^b   Wang, Linbo ^a   Yen, Yun ^a,b,d  

^a ZHEJIANG UNIVERSITY   (China)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE LARGE SUBUNIT M1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL PROLIFERATION; CHINA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL PREDICTION; TUMOR VOLUME; UNDIFFERENTIATED CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS P21(RAS); RAF KINASES; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84880799738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070191     Document Type: Article

References (49)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Kamangar F, Dores GM, Anderson WF, (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150.
3. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, et al. (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303: 1729-1737.
4. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730.
5. Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, et al. (2005) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev: CD004064.
6. Ohtsu A, Yoshida S, Saijo N, (2006) Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 24: 2188-2196.
7. The World Cancer Report-the major findings. Cent Eur J Public Health 11: 177-179.
8. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ, (2009) Gastric cancer. Lancet 374: 477-490.
9. Gravalos C, Jimeno A, (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523-1529.
10. Nordlund P, Reichard P, (2006) Ribonucleotide reductases. Annu Rev Biochem 75: 681-706.
11. Lori F, Lisziewicz J, (1999) Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects. Antivir Ther 4Suppl 3: 101-108.
12. Elnaggar M, Giovannetti E, Peters GJ, (2012) Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Curr Pharm Des 18: 2811-2829.
13. Madaan K, Kaushik D, Verma T, (2012) Hydroxyurea: a key player in cancer chemotherapy. Expert Rev Anticancer Ther 12: 19-29.
14. Demetter P, Marechal R, Verset L, Salmon I, Bachet JB, et al. (2012) Molecular changes in pancreatic cancer: implications for molecular targeting therapy. Acta Gastroenterol Belg 75: 210-214.
15. Zhang K, Hu S, Wu J, Chen L, Lu J, et al. (2009) Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer 8: 11.
16. Xu X, Page JL, Surtees JA, Liu H, Lagedrost S, et al. (2008) Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. Cancer Res 68: 2652-2660.
17. Fisher SB, Patel SH, Bagci P, Kooby DA, El-Rayes BF, et al. (2012) An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment. Cancer.
18. Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, et al. (2010) Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol 41: 1742-1748.
19. Liu X, Lai L, Wang X, Xue L, Leora S, et al. (2011) Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer. Cancer Res 71: 3202-3213.
20. Liu X, Zhou B, Xue L, Shih J, Tye K, et al. (2006) Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res 12: 6337-6344.
21. Fan H, Huang A, Villegas C, Wright JA, (1997) The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci U S A 94: 13181-13186.
22. Fan H, Villegas C, Wright JA, (1996) Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci U S A 93: 14036-14040.
23. Zheng Z, Chen T, Li X, Haura E, Sharma A, et al. (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356: 800-808.
24. Bepler G, Sharma S, Cantor A, Gautam A, Haura E, et al. (2004) RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 22: 1878-1885.
25. Zhang GB, Chen J, Wang LR, Li J, Li MW, et al. (2012) RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer. Cancer Chemother Pharmacol 69: 1277-1287.
26. Gautam A, Li ZR, Bepler G, (2003) RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 22: 2135-2142.
27. Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, et al. (2008) Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98: 1710-1715.
28. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, et al. (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10: 1318-1325.
29. Lee JJ, Maeng CH, Baek SK, Kim GY, Yoo JH, et al. (2010) The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 70: 205-210.
30. Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, et al. (2007) Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120: 1355-1363.
31. Cerqueira NM, Fernandes PA, Ramos MJ, (2007) Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat Anticancer Drug Discov 2: 11-29.
32. Jordheim LP, Seve P, Tredan O, Dumontet C, (2011) The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 12: 693-702.
33. Zhou B, Phan V, Liu X, Juhasz A, Chu PG, et al. (2006) Production of a monoclonal antibody against the hRRM2 subunit of ribonucleotide reductase and immunohistochemistry study of human cancer tissues. Hybridoma (Larchmt) 25: 264-270.
34. Qiu W, Zhou B, Darwish D, Shao J, Yen Y, (2006) Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits. Biochem Biophys Res Commun 340: 428-434.
35. Sherman PA, Fyfe JA, (1989) Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem 180: 222-226.
36. Sano T, (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14: 101-112.
37. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, et al. (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548-3553.
38. Liu X, Zhou B, Xue L, Shih J, Tye K, et al. (2005) The ribonucleotide reductase subunit M2B subcellular localization and functional importance for DNA replication in physiological growth of KB cells. Biochem Pharmacol 70: 1288-1297.
39. Zhou BS, Tsai P, Ker R, Tsai J, Ho R, et al. (1998) Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 16: 43-49.
40. Song MS, Salmena L, Pandolfi PP, (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13: 283-296.
41. Tanwar PS, Kaneko-Tarui T, Lee HJ, Zhang L, Teixeira JM (2013) PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression. Carcinogenesis.
42. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, et al. (2012) Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72: 1878-1889.
43. Wonganan P, Chung WG, Zhu S, Kiguchi K, Digiovanni J, et al. (2012) Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells. Cancer Biol Ther 13: 908-914.
44. Correale P, Fulfaro F, Marsili S, Cicero G, Bajardi E, et al. (2005) Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. Cancer Chemother Pharmacol 56: 563-568.
45. Kurata N, Fujita H, Ohuchida K, Mizumoto K, Mahawithitwong P, et al. (2011) Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. Int J Oncol 39: 473-482.
46. Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, et al. (2009) Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27: 5808-5815.
47. Wang X, Zhao J, Yang L, Mao L, An T, et al. (2010) Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol 27: 484-490.
48. Morikawa T, Maeda D, Kume H, Homma Y, Fukayama M, (2010) Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology 57: 885-892.
49. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284.